Formulation and Evaluation of Solid Lipid Nanoparticles Loaded with Orlistat for Enhanced Oral Bioavailability

Pulla Reddy Institute of Pharmacy, Hyderabad, India

*Corresponding author: Dr. B Ravindra Babu, Pulla Reddy Institute of Pharmacy, Department of Pharmaceutics, Domadugu, Gummadidala (M), Sangareddy District, Telangana State, India, E-mail: [email protected]

Received Date: January 02, 2025

Published Date: January 28, 2025

Citation: Ravindra Babu B, et al. (2025). Formulation and Evaluation of Solid Lipid Nanoparticles Loaded with Orlistat for Enhanced Oral Bioavailability. Mathews J Pharma Sci. 9(1):43.

Copyrights: Ravindra Babu B, et al. © (2025).

ABSTRACT

Orlistat, a potent anti-obesity agent, suffers from poor solubility and bioavailability, limiting its therapeutic efficacy. This study aimed to develop solid lipid nanoparticles (SLNs) as an advanced drug delivery system to enhance Orlistat’s therapeutic profile. Orlistat-loaded SLNs were prepared using solvent evaporation and high-pressure homogenization techniques. Characterization included particle size, zeta potential, encapsulation efficiency, and in-vitro drug release. The optimized SLNs exhibited a mean particle size of 200 nm, zeta potential of -25 mV, and encapsulation efficiency exceeding 85%. Stability studies confirmed the robustness of SLNs under various storage conditions, while drug release studies revealed a biphasic release profile. These findings support the use of SLNs to improve the bioavailability and therapeutic outcomes of poorly soluble drugs like Orlistat. In conclusion, Orlistat-loaded SLNs demonstrated significant improvement in drug delivery efficiency, offering a promising alternative for obesity management.